The United Laboratories International Holdings Limited
聯邦制藥
- Listing
- HKEX 03933
Clinical-stage assets
| Asset | Stage at source date | Indication | Source date |
|---|---|---|---|
| UBT251 | Phase 2 initiated in China for overweight or obesity | 2025-03-24 |
Licensing announcements since 2025
| Date | Counterparty | Asset / platform | Upfront | Near-term | Potential total | Stage at announcement |
|---|---|---|---|---|---|---|
| 2025-03-24 | Novo Nordisk A/S | UBT251 | USD 200,000,000 | Phase 2 initiated in China for overweight or obesity |